questionsmedicales.fr
Hémopathies et maladies lymphatiques
Hémopathies
Tumeurs hématologiques
Tumeurs hématologiques : Questions médicales fréquentes
Diagnostic
5
Leucémie
Biopsie
Analyse sanguine
Lymphome
Imagerie médicale
Biopsie
Cytométrie en flux
Cellules sanguines
Néoplasies hématologiques
Marqueurs tumoraux
Tumeurs hématologiques
CD19
Imagerie médicale
Lymphomes
Diagnostic
Symptômes
5
Leucémie
Symptômes
Fatigue
Lymphome
Ganglions lymphatiques
Symptômes
Myélome
Douleurs osseuses
Tests sanguins
Fatigue
Perte de poids
Infections
Saignements
Anomalies sanguines
Tumeurs hématologiques
Prévention
5
Prévention
Tumeurs hématologiques
Toxines
Tabagisme
Leucémie
Facteurs de risque
Produits chimiques
Benzène
Risque
Infections virales
Virus d'Epstein-Barr
Lymphomes
Alimentation saine
Système immunitaire
Prévention
Traitements
5
Leucémie
Chimiothérapie
Greffe de moelle osseuse
Lymphome
Chimiothérapie
Immunothérapie
Thérapie ciblée
Myélome
Traitement
Greffe de moelle osseuse
Tumeurs hématologiques
Traitement
Effets secondaires
Chimiothérapie
Infections
Complications
5
Leucémie
Complications
Infections
Lymphome
Complications
Infections
Greffe de moelle osseuse
Infections
Chimiothérapie
Tumeurs hématologiques
Risque de cancer
Traitement
Complications
Suivi médical
Traitement
Facteurs de risque
5
Myélome
Facteurs de risque
Âge avancé
Antécédents médicaux
Radiations
Risque
Sexe
Tumeurs hématologiques
Risque
Maladies auto-immunes
Risque
Tumeurs hématologiques
Radiations ionisantes
Facteurs de risque
Néoplasies
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Tumeurs hématologiques : Questions médicales les plus fréquentes",
"headline": "Tumeurs hématologiques : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Tumeurs hématologiques : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-27",
"dateModified": "2026-04-16",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Tumeurs hématologiques"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Hémopathies",
"url": "https://questionsmedicales.fr/mesh/D006402",
"about": {
"@type": "MedicalCondition",
"name": "Hémopathies",
"code": {
"@type": "MedicalCode",
"code": "D006402",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C15.378"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Tumeurs de la moelle osseuse",
"alternateName": "Bone Marrow Neoplasms",
"url": "https://questionsmedicales.fr/mesh/D019046",
"about": {
"@type": "MedicalCondition",
"name": "Tumeurs de la moelle osseuse",
"code": {
"@type": "MedicalCode",
"code": "D019046",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C15.378.400.200"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Polyglobulie primitive essentielle",
"alternateName": "Polycythemia Vera",
"url": "https://questionsmedicales.fr/mesh/D011087",
"about": {
"@type": "MedicalCondition",
"name": "Polyglobulie primitive essentielle",
"code": {
"@type": "MedicalCode",
"code": "D011087",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C15.378.400.200.500"
}
}
}
]
}
],
"about": {
"@type": "MedicalCondition",
"name": "Tumeurs hématologiques",
"alternateName": "Hematologic Neoplasms",
"code": {
"@type": "MedicalCode",
"code": "D019337",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Ying Wang",
"url": "https://questionsmedicales.fr/author/Ying%20Wang",
"affiliation": {
"@type": "Organization",
"name": "Department of Intensive Care Medicine, Shanghai Children's Medical Center, Shanghai Jiaotong University School of Medicine, Shanghai, China."
}
},
{
"@type": "Person",
"name": "Chunfeng Wang",
"url": "https://questionsmedicales.fr/author/Chunfeng%20Wang",
"affiliation": {
"@type": "Organization",
"name": "School of Nursing, Fujian Medical University, No. 1 Xueyuan Road, Shangjie, Minhou, Fuzhou, Fujian, China."
}
},
{
"@type": "Person",
"name": "Yong Wu",
"url": "https://questionsmedicales.fr/author/Yong%20Wu",
"affiliation": {
"@type": "Organization",
"name": "Department of Hematology, Fujian Medical University Union Hospital, No. 29 Xinquan Road, Fuzhou, Fujian, China. wuyong9195@126.com."
}
},
{
"@type": "Person",
"name": "Rong Hu",
"url": "https://questionsmedicales.fr/author/Rong%20Hu",
"affiliation": {
"@type": "Organization",
"name": "School of Nursing, Fujian Medical University, No. 1 Xueyuan Road, Shangjie, Minhou, Fuzhou, Fujian, China. ronghu1246@fjmu.edu.cn."
}
},
{
"@type": "Person",
"name": "Jingyi Chen",
"url": "https://questionsmedicales.fr/author/Jingyi%20Chen",
"affiliation": {
"@type": "Organization",
"name": "School of Nursing, Fujian Medical University, No. 1 Xueyuan Road, Shangjie, Minhou, Fuzhou, Fujian, China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "[Blastic plasmacytoid dendritic cell neoplasm (BPDCN) : A rare hematologic neoplasm with frequent cutaneous involvement].",
"datePublished": "2023-07-05",
"url": "https://questionsmedicales.fr/article/37407876",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00105-023-05192-9"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cognitive Trajectories in Older Adults Diagnosed With Hematologic Malignant Neoplasms.",
"datePublished": "2024-08-01",
"url": "https://questionsmedicales.fr/article/39212987",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1001/jamanetworkopen.2024.31057"
}
},
{
"@type": "ScholarlyArticle",
"name": "Hematologic Neoplasms Associated with Down Syndrome: Cellular and Molecular Heterogeneity of the Diseases.",
"datePublished": "2023-10-18",
"url": "https://questionsmedicales.fr/article/37895004",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijms242015325"
}
},
{
"@type": "ScholarlyArticle",
"name": "Clinical Validation of FusionPlex RNA Sequencing and Its Utility in the Diagnosis and Classification of Hematologic Neoplasms.",
"datePublished": "2023-10-07",
"url": "https://questionsmedicales.fr/article/37813298",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jmoldx.2023.09.007"
}
},
{
"@type": "ScholarlyArticle",
"name": "Epidemiology of Cancer-Associated Venous Thromboembolism in Patients With Solid and Hematologic Neoplasms in the Veterans Affairs Health Care System.",
"datePublished": "2023-06-01",
"url": "https://questionsmedicales.fr/article/37306999",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1001/jamanetworkopen.2023.17945"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Hémopathies et maladies lymphatiques",
"item": "https://questionsmedicales.fr/mesh/D006425"
},
{
"@type": "ListItem",
"position": 3,
"name": "Hémopathies",
"item": "https://questionsmedicales.fr/mesh/D006402"
},
{
"@type": "ListItem",
"position": 4,
"name": "Tumeurs hématologiques",
"item": "https://questionsmedicales.fr/mesh/D019337"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Tumeurs hématologiques - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Tumeurs hématologiques",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-05-09",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Tumeurs hématologiques",
"description": "Comment diagnostique-t-on une leucémie ?\nQuels tests sont utilisés pour le lymphome ?\nQu'est-ce qu'une cytométrie en flux ?\nQuels marqueurs tumoraux sont recherchés ?\nQuelle est l'importance de l'imagerie dans le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D019337#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Tumeurs hématologiques",
"description": "Quels sont les symptômes de la leucémie ?\nComment se manifeste un lymphome ?\nQuels signes indiquent un myélome ?\nY a-t-il des symptômes généraux à surveiller ?\nLes saignements sont-ils un symptôme courant ?",
"url": "https://questionsmedicales.fr/mesh/D019337#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Tumeurs hématologiques",
"description": "Peut-on prévenir les tumeurs hématologiques ?\nLe tabagisme est-il un facteur de risque ?\nL'exposition à des produits chimiques est-elle dangereuse ?\nLes infections virales jouent-elles un rôle ?\nUne alimentation saine peut-elle aider ?",
"url": "https://questionsmedicales.fr/mesh/D019337#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Tumeurs hématologiques",
"description": "Quels traitements sont disponibles pour la leucémie ?\nComment traite-t-on un lymphome ?\nQu'est-ce que la thérapie ciblée ?\nLa greffe de moelle osseuse est-elle courante ?\nQuels sont les effets secondaires des traitements ?",
"url": "https://questionsmedicales.fr/mesh/D019337#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Tumeurs hématologiques",
"description": "Quelles complications peuvent survenir avec la leucémie ?\nLe lymphome peut-il entraîner des complications ?\nQuels sont les risques après une greffe de moelle osseuse ?\nLes tumeurs hématologiques augmentent-elles le risque de cancer ?\nComment gérer les complications liées aux traitements ?",
"url": "https://questionsmedicales.fr/mesh/D019337#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Tumeurs hématologiques",
"description": "Quels sont les facteurs de risque pour le myélome ?\nLes antécédents médicaux influencent-ils le risque ?\nLe sexe joue-t-il un rôle dans le risque ?\nLes maladies auto-immunes sont-elles un facteur de risque ?\nL'exposition à des radiations est-elle préoccupante ?",
"url": "https://questionsmedicales.fr/mesh/D019337#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostique-t-on une leucémie ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un diagnostic de leucémie se fait par des analyses sanguines et une biopsie de moelle osseuse."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour le lymphome ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent des examens d'imagerie, des biopsies et des analyses sanguines."
}
},
{
"@type": "Question",
"name": "Qu'est-ce qu'une cytométrie en flux ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "C'est une technique utilisée pour analyser les cellules sanguines et diagnostiquer des néoplasies."
}
},
{
"@type": "Question",
"name": "Quels marqueurs tumoraux sont recherchés ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des marqueurs comme CD19, CD20 et CD34 peuvent indiquer des tumeurs hématologiques."
}
},
{
"@type": "Question",
"name": "Quelle est l'importance de l'imagerie dans le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'imagerie aide à visualiser les masses lymphatiques et à évaluer l'étendue de la maladie."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes de la leucémie ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent fatigue, fièvre, infections fréquentes et saignements."
}
},
{
"@type": "Question",
"name": "Comment se manifeste un lymphome ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un lymphome peut se manifester par des ganglions enflés, de la fièvre et des sueurs nocturnes."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent un myélome ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent douleurs osseuses, fatigue, et anomalies dans les tests sanguins."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes généraux à surveiller ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, fatigue inexpliquée, perte de poids et infections fréquentes sont des signes à surveiller."
}
},
{
"@type": "Question",
"name": "Les saignements sont-ils un symptôme courant ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des saignements inhabituels peuvent indiquer une anomalie sanguine liée à ces tumeurs."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les tumeurs hématologiques ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de méthode de prévention garantie, mais éviter les toxines peut aider."
}
},
{
"@type": "Question",
"name": "Le tabagisme est-il un facteur de risque ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme est associé à un risque accru de certains types de leucémie."
}
},
{
"@type": "Question",
"name": "L'exposition à des produits chimiques est-elle dangereuse ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à des produits chimiques comme le benzène peut augmenter le risque."
}
},
{
"@type": "Question",
"name": "Les infections virales jouent-elles un rôle ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections virales, comme le virus d'Epstein-Barr, sont liées à des lymphomes."
}
},
{
"@type": "Question",
"name": "Une alimentation saine peut-elle aider ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée peut soutenir le système immunitaire, mais ne prévient pas directement."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour la leucémie ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent chimiothérapie, radiothérapie et greffe de moelle osseuse."
}
},
{
"@type": "Question",
"name": "Comment traite-t-on un lymphome ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement peut comprendre chimiothérapie, radiothérapie et immunothérapie."
}
},
{
"@type": "Question",
"name": "Qu'est-ce que la thérapie ciblée ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "C'est un traitement qui cible spécifiquement les cellules cancéreuses, souvent utilisé dans les myélomes."
}
},
{
"@type": "Question",
"name": "La greffe de moelle osseuse est-elle courante ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle est souvent utilisée pour traiter les tumeurs hématologiques avancées."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires des traitements ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires peuvent inclure nausées, fatigue, et risque accru d'infections."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec la leucémie ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent infections graves, saignements et défaillance organique."
}
},
{
"@type": "Question",
"name": "Le lymphome peut-il entraîner des complications ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut causer des infections, des complications pulmonaires et des problèmes de coagulation."
}
},
{
"@type": "Question",
"name": "Quels sont les risques après une greffe de moelle osseuse ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les risques incluent le rejet de greffe, infections et complications liées à la chimiothérapie."
}
},
{
"@type": "Question",
"name": "Les tumeurs hématologiques augmentent-elles le risque de cancer ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les patients peuvent avoir un risque accru de développer d'autres cancers après traitement."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications liées aux traitements ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion inclut un suivi médical régulier et des traitements symptomatiques appropriés."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour le myélome ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'âge avancé, l'obésité et des antécédents familiaux de myélome."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux influencent-ils le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents de troubles sanguins ou d'exposition à des radiations augmentent le risque."
}
},
{
"@type": "Question",
"name": "Le sexe joue-t-il un rôle dans le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains types de tumeurs hématologiques sont plus fréquents chez les hommes."
}
},
{
"@type": "Question",
"name": "Les maladies auto-immunes sont-elles un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines maladies auto-immunes peuvent augmenter le risque de développer des tumeurs hématologiques."
}
},
{
"@type": "Question",
"name": "L'exposition à des radiations est-elle préoccupante ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à des radiations ionisantes est un facteur de risque connu pour ces néoplasies."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 16/04/2026
Contenu vérifié selon les dernières recommandations médicales
5 publications dans cette catégorie
Affiliations :
Department of Intensive Care Medicine, Shanghai Children's Medical Center, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Publications dans "Tumeurs hématologiques" :
4 publications dans cette catégorie
Affiliations :
School of Nursing, Fujian Medical University, No. 1 Xueyuan Road, Shangjie, Minhou, Fuzhou, Fujian, China.
Publications dans "Tumeurs hématologiques" :
4 publications dans cette catégorie
Affiliations :
Department of Hematology, Fujian Medical University Union Hospital, No. 29 Xinquan Road, Fuzhou, Fujian, China. wuyong9195@126.com.
Publications dans "Tumeurs hématologiques" :
4 publications dans cette catégorie
Affiliations :
School of Nursing, Fujian Medical University, No. 1 Xueyuan Road, Shangjie, Minhou, Fuzhou, Fujian, China. ronghu1246@fjmu.edu.cn.
Publications dans "Tumeurs hématologiques" :
3 publications dans cette catégorie
Affiliations :
School of Nursing, Fujian Medical University, No. 1 Xueyuan Road, Shangjie, Minhou, Fuzhou, Fujian, China.
Publications dans "Tumeurs hématologiques" :
2 publications dans cette catégorie
Affiliations :
Division of Hematology, Department of Human Pathology in Adulthood and Childhood "Gaetano Barresi", University of Messina, 98125 Messina, Italy.
Publications dans "Tumeurs hématologiques" :
2 publications dans cette catégorie
Affiliations :
Institute for Biomedical Research and Innovation (IRIB), National Research Council of Italy (CNR), 98164 Messina, Italy.
Publications dans "Tumeurs hématologiques" :
2 publications dans cette catégorie
Affiliations :
School of Allergy and Clinical Immunology, Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy.
Publications dans "Tumeurs hématologiques" :
2 publications dans cette catégorie
Affiliations :
EPI-PHARE (French National Agency for Medicines and Health Products Safety (ANSM) and French National Health Insurance (CNAM)), 143 Boulevard Anatole, 93200 Saint-Denis, France. Marie-Joelle.JABAGI@ansm.sante.fr.
Publications dans "Tumeurs hématologiques" :
2 publications dans cette catégorie
Affiliations :
Aix-Marseille Univ, Inserm, CNRS, Institut Paoli-Calmettes, CRCM, 13009 Marseille, France. goncalvesa@ipc.unicancer.fr.
Publications dans "Tumeurs hématologiques" :
2 publications dans cette catégorie
Affiliations :
Aix-Marseille Univ, Inserm, CNRS, Institut Paoli-Calmettes, CRCM, 13009 Marseille, France. veyn@ipc.unicancer.fr.
Publications dans "Tumeurs hématologiques" :
2 publications dans cette catégorie
Affiliations :
EPI-PHARE (French National Agency for Medicines and Health Products Safety (ANSM) and French National Health Insurance (CNAM)), 143 Boulevard Anatole, 93200 Saint-Denis, France. thien.le-tri@ansm.sante.fr.
Publications dans "Tumeurs hématologiques" :
2 publications dans cette catégorie
Affiliations :
EPI-PHARE (French National Agency for Medicines and Health Products Safety (ANSM) and French National Health Insurance (CNAM)), 143 Boulevard Anatole, 93200 Saint-Denis, France. mahmoud.zureik@ansm.sante.fr.
Versailles Saint-Quentin-en-Yvelines University, 78000 Versailles, France. mahmoud.zureik@ansm.sante.fr.
Publications dans "Tumeurs hématologiques" :
2 publications dans cette catégorie
Affiliations :
EPI-PHARE (French National Agency for Medicines and Health Products Safety (ANSM) and French National Health Insurance (CNAM)), 143 Boulevard Anatole, 93200 Saint-Denis, France. rosemary.dray-spira@ansm.sante.fr.
Publications dans "Tumeurs hématologiques" :
2 publications dans cette catégorie
Affiliations :
Departamento de Medicina, Universidad de Santiago de Compostela, Santiago, Spain; Unidad de Farmacia Oncológica, Servicio de Farmacia, Hospital Clínico, Universitario de Santiago de Compostela, Santiago, Spain; Grupo de Farmacología, Instituto de Investigación Santiago de Compostela (IDIS), Santiago, Spain. Electronic address: beatriz.bernardez.ferran@sergas.es.
Publications dans "Tumeurs hématologiques" :
2 publications dans cette catégorie
Affiliations :
Unidad de Farmacia Oncológica, Servicio de Farmacia, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
Publications dans "Tumeurs hématologiques" :
2 publications dans cette catégorie
Affiliations :
Servicio de Farmacia, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain.
Publications dans "Tumeurs hématologiques" :
2 publications dans cette catégorie
Affiliations :
Servicio de Farmacia, Hospital Universitario Virgen Macarena, Sevilla, Spain.
Publications dans "Tumeurs hématologiques" :
2 publications dans cette catégorie
Affiliations :
Servicio de Farmacia, Corporació de Salut del Maresme i la Selva, Calella, Barcelona, Spain.
Publications dans "Tumeurs hématologiques" :
2 publications dans cette catégorie
Affiliations :
Unidad de Farmacia Oncológica, Servicio de Farmacia, Hospital Universitario Puerta del mar, Cádiz, Spain.
Publications dans "Tumeurs hématologiques" :
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy that derives from precursors of plasmacytoid dendritic cells and is characterized by disseminated, erythematous ...
More people are surviving long-term after diagnosis with hematologic malignant neoplasm (HMN), yet there are limited data on cancer-related cognitive impairment in people with HMN. Better understandin...
To model cognitive trajectories and rates of cognitive decline before and after HMN diagnosis in older adults compared with a matched noncancer cohort....
In this population-based cohort study, older adults from the Health and Retirement Study (HRS) diagnosed with HMN between 1998 and 2016 after age 65 years were matched 1:3 to participants without canc...
HMN diagnosis by Medicare diagnosis codes....
Cognitive function was assessed by the Langa-Weir cognitive summary score from 1992 to 2020. Sociodemographic and health-related variables relevant to cognition were incorporated into propensity score...
At baseline, there were 668 participants in the HMN cohort (mean [SD] age, 76.8 [7.6] years; 343 [51.3%] male; 72 [10.8%] Black, 33 [4.9%] Hispanic, and 585 [87.6%] White) and 1994 participants in the...
In this cohort study of older adults, the HMN and matched noncancer control cohorts had similar rates of cognitive decline before, during, and after diagnosis after accounting for the competing risk o...
The molecular basis of Down syndrome (DS) predisposition to leukemia is not fully understood but involves various factors such as chromosomal abnormalities, oncogenic mutations, epigenetic alterations...
Recurrent gene rearrangements result in gene fusions that encode chimeric proteins, driving the pathogenesis of many hematologic neoplasms. The fifth edition World Health Organization classification a...
Identifying changes in epidemiologic patterns of the incidence and risk of cancer-associated thrombosis (CAT), particularly with evolving cancer-directed therapy, is essential for risk stratification....
To assess the incidence of CAT over time and to determine pertinent patient-specific, cancer-specific, and treatment-specific factors associated with its risk....
This longitudinal, retrospective cohort study was conducted from 2006 to 2021. Duration of follow-up was from the date of diagnosis until first venous thromboembolism (VTE) event, death, loss of follo...
Newly diagnosed invasive solid tumors and hematologic neoplasms....
Incidence of VTE was assessed using a combination of International Classification of Diseases, Ninth Revision, Clinical Modification and International Statistical Classification of Diseases, Tenth Rev...
A total of 434 203 patients (420 244 men [96.8%]; median [IQR] age, 67 [62-74] years; 7414 Asian or Pacific Islander patients [1.7%]; 20 193 Hispanic patients [4.7%]; 89 371 non-Hispanic Black patient...
In this cohort study of patients with cancer, a high incidence of VTE was observed, with yearly trends that remained stable over the 16-year study period. Both novel and known factors associated with ...
The COVID-19 pandemic has led to a reduction in routine in-person medical care; however, it is unknown whether there have been any changes in visit rates among patients with hematologic neoplasms....
To examine associations between the COVID-19 pandemic and in-person visits and telemedicine use among patients undergoing active treatment for hematologic neoplasms....
Data for this retrospective observational cohort study were obtained from a nationwide electronic health record-derived, deidentified database. Data for patients with hematologic neoplasms who had rec...
Monthly visit rates were calculated as the number of documented visits (telemedicine or in-person) per active patient per 30-day period. We used time-series forecasting methods on prepandemic data (Ma...
This study included data for 24 261 patients, with a median age of 68 years (IQR, 60-75 years). A total of 6737 patients received oral therapy, 15 314 received outpatient infusions, and 8316 received ...
In this cohort study of patients with hematologic neoplasms, documented in-person visit rates for those receiving oral therapy and outpatient infusions significantly decreased during the early pandemi...
The frequency and clinical phenotypes of cardiotoxic events in chimeric antigen receptor (CAR) T-cell recipients remain poorly understood given that landmark approval trials typically exclude patients...
To summarize the prevalence of adverse cardiovascular events among adults receiving CAR T-cell therapies for advanced hematologic malignant neoplasms....
MEDLINE, Embase, Cochrane Library, and Google Scholar were systematically searched from database inception until February 26, 2024....
Observational studies were included if they comprised adult CAR T-cell recipients with advanced hematologic malignant neoplasms and if they systematically evaluated cardiovascular complications....
Extraction of prespecified parameters related to the patient population, study design, and clinical events was performed at the study level by 2 independent reviewers in accordance with the Meta-Analy...
Ventricular and supraventricular arrhythmias, heart failure events, reduction in left ventricular ejection fraction, myocardial infarction, and cardiovascular and all-cause mortality....
Thirteen studies comprising 1528 CAR T-cell recipients (median [IQR] age, 61 [58.7-63.0] years; 1016 males [66%]; 80% patients with lymphoma) were included. The median (IQR) duration of follow-up was ...
This meta-analysis found a low prevalence of ventricular arrhythmia, myocardial infarction, and cardiovascular death among CAR T-cell recipients over a short-term to midterm follow-up. Left ventricula...
Hematology represents a dynamic specialty in clinical medicine that requires solid knowledge of normal and pathological hematopoiesis, cytomorphology, pathology, immunology, genetics and molecular bio...
Eosinophils in peripheral blood account for 0.3-5% of leukocytes, which is equivalent to 0.05-0.5 × 10...
Plasmacytoid dendritic cells (pDCs) are a specific dendritic cell type stemming from the myeloid lineage. Clinically and pathologically, neoplasms associated with pDCs are classified as blastic plasma...